Byeng Su Kwon

Title: Byeng Su Kwon: Innovator in Anticancer Prodrug Development

Introduction

Byeng Su Kwon is a notable inventor based in Jeonju, South Korea. He has made significant contributions to the field of cancer treatment through his innovative research and development of hybrid anticancer prodrugs. His work focuses on creating effective therapeutic agents that can enhance the efficacy of cancer treatments.

Latest Patents

Byeng Su Kwon holds a patent for a hybrid anticancer prodrug that simultaneously produces cinnamaldehyde and quinone methide. This invention is designed to sequentially release these compounds in response to specific conditions, such as the presence of HO and acidic pH. The prodrug works by alkylating the antioxidant GSH, inhibiting the antioxidative system, and increasing oxidative stress. This process generates and accumulates reactive oxygen species (ROS), promoting apoptosis in cancer cells. The hybrid anticancer prodrug is positioned as a promising candidate for anticancer drug development due to its dual stimulus-response mechanism and cancer cell-specific treatment action.

Career Highlights

Byeng Su Kwon is affiliated with Chonbuk National University, where he conducts his research and development activities. His academic and professional journey has been marked by a commitment to advancing cancer treatment methodologies through innovative approaches.

Collaborations

He has collaborated with notable colleagues, including Joung Youn Noh and Dong Cho Han, to further enhance the research and development of anticancer therapies. Their combined expertise contributes to the advancement of knowledge in this critical field.

Conclusion

Byeng Su Kwon's work in developing hybrid anticancer prodrugs represents a significant advancement in cancer treatment. His innovative approach and dedication to research continue to pave the way for new therapeutic options in oncology.